RBC Capital analyst Andrew Wong maintains Nutrien (NYSE:NTR) with a Outperform and raises the price target from $73 to $80.
Forward Pharma Announced Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
Forward Pharma A/S (NASDAQ: FWP) ("we" or "Forward"), today announced that that on December 16, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying us that Nasdaq believes that Forward is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no lon
